LONDON, UK, 9 October 2013 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, announces that it has agreed terms to supply 100 Daytona ultra-widefield retinal imaging devices to HVHC, Inc. for installation in its Visionworks’ optometry stores in the USA.
HVHC, Inc. is a leading provider of eye care services in the USA with more than 600 Visionworks optical retail stores in 40 states and the District of Columbia. The order for 100 Daytonas will be delivered during the 12-month period commencing September 2013.
Roy Davis, CEO, commented: “We are delighted to announce this important order with HVHC and Visionworks, a leading provider of eye care services in the USA. Visionworks is a significant North American chain and this order follows the recent material contract for 410 Daytona in Australia and New Zealand, demonstrating the potential that we believe Daytona offers to eye care professionals worldwide. We reiterate our full year guidance of 1,000 to 1,200 Daytona installations for the current financial year.”
Jeff Smith, Chief Medical Officer of HVHC Inc, added: “We are excited to have the Daytona technology available in the Visionworks locations which we believe will enhance the patient experience.”
Roy Davis, CEO
Rob Kennedy, Interim CFO
|Tel: 01383 843 300
Dr. Florian Safner, VP of Professional Services
|Tel: +1 210-245-2405|
Ben Atwell / Simon Conway / Mo Noonan
|Tel: 020 7831 3113|
Note to Editors: Images available upon request
Optos plc has the vision to be The retina company. We aim to be recognised as a leading provider of devices and solutions to eyecare professionals for improved patient care. Optos' core devices produce ultra widefield, high resolution digital images (optomaps®) of approximately 82% of the retina, something no other device is capable of doing in any one image.
Optos has a range of imaging devices that support different customer segments and patient levels: the P200 and 200Dx devices are concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; the P200C devices are designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; and the P200MA and 200Tx devices supports ophthalmologists and retinal specialists in the medical care market.
Daytona represents the next generation of Optos ultra-widefield retinal imaging technology, and has been scaled to accommodate smaller office spaces while providing high resolution imaging, and adding new auto-fluorescence capabilities. Weighing only about 25 kg, Daytona’s new, ergonomic body is designed to increase patient comfort, as well as make it easier to correctly position the eye. In addition to the smaller, sleeker design, Daytona features an improved user interface with its intuitive, workflow based software. Daytona also offers “plug-n-play” installation, a modular robust build-design to simplify product support, image review capabilities and electronic image storage options. Daytona was designed to allow the globalisation of the core Optos imaging technology, giving the opportunity to offer the benefits of optomaps® technology to more eyecare professionals and their patients around the world.
The acquisition of OPKO instrumentation in October 2011 brought the group optical coherence tomography (“OCT”) diagnostic devices and optical ultrasound scanners, used in the diagnosis and management of eye disease and conditions. Optos’ widefield retinal imaging technology, combined with the specific data that can be derived from OCT images, has the potential to offer ophthalmologists and optometrists the most powerful tools for disease diagnosis and management. The optomaps® images provide enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. OCT delivers an image that shows a three dimensional, cross-sectional view of the retina in any particular area, typically in the central pole area of the retina around the optic nerve and macula and is used to detect the presence of and understand the severity of disease, determine treatment approaches and monitor post-treatment effect.
Our expanded product range now includes ultra-widefield imaging, OCT, visual acuity, perimetry and treatment laser products.
For more information please visit our website www.optos.com.
HVHC, Inc. is the leader of integrated vision care solutions for the value-seeking customer, offering differentiated products and services via its three divisions: national optical retailer Visionworks, managed vision care provider Davis Vision, and wholesale eyewear distributor Viva International. HVHC has more than 8,600 employees and operates in seven countries, 40 states and the District of Columbia. Headquartered in San Antonio, HVHC is the largest wholly owned and operated U.S.-based optical company. Learn more about HVHC, Inc., at www.hvhcretail.com.
Visionworks (formerly Eye Care Centers of America, Inc.) is a leading provider of eye care services with 600 optical retail stores in 40 states and the District of Columbia through 5 store names that are leaders in eye care service in each of their respective markets.
Visionworks is committed to providing their customers with an excellent shopping experience and high quality products and service with the best value and selection in the industry. All stores offer designer and exclusive brand frames, lenses, sunglasses and accessories along with leading technology in vision correction. Visionworks’ comprehensive service offerings include contact lens dispensing, in-store labs which provide one-hour service on many prescriptions at nearly all locations and doctors of optometry at or next to every store providing comprehensive eye exams. Visionworks is a wholly owned subsidiary of HVHC, Inc.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.